Mar 8, 2021 4:05 pm EST Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk
Feb 22, 2021 7:00 am EST Castle Biosciences to Release Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Monday, March 8, 2021
Feb 4, 2021 7:00 am EST Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Annual South Beach Symposium
Jan 20, 2021 7:00 am EST Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference
Jan 13, 2021 7:00 am EST Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results
Jan 4, 2021 7:00 am EST Castle Biosciences to Present at the 23rd Annual Needham Virtual Growth Conference
Dec 18, 2020 5:00 pm EST Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
